Format

Send to

Choose Destination
Cold Spring Harb Perspect Med. 2015 Mar 2;5(3):a021493. doi: 10.1101/cshperspect.a021493.

Prevention of hepatitis B.

Author information

1
Department of Pediatrics, National Taiwan University Hospital, Taipei 10016, Taiwan Hepatitis Research Center, National Taiwan University Hospital, Taipei 10016, Taiwan.
2
Hepatitis Research Center, National Taiwan University Hospital, Taipei 10016, Taiwan Internal Medicine, National Taiwan University Hospital, Taipei 10016, Taiwan Genomics Research Center, Academia Sinica, Nankang 11529, Taiwan.

Abstract

Hepatitis B virus (HBV) causes life-threatening liver disease. It is transmitted through a horizontal route or a mother-to-infant route, and the latter is the major route in endemic areas. Prevention of HBV infection by immunization is the best way to eliminate HBV-related diseases. The HBV vaccine is the first human vaccine using a viral antigen from infected persons, which is safe and effective. Either passive immunization by hepatitis B immunoglobulin (HBIG) or active immunization by HBV vaccine is effective, and a combination of both yields the best efficacy in preventing HBV infection. The impact of universal HBV immunization is huge, with 90%-95% effectiveness in preventing chronic HBV infection. It is the first cancer preventive vaccine with a protective efficacy against hepatocellular carcinoma (HCC) of ∼ 70%. Nevertheless, further effort is still needed to avoid vaccine failure and to increase the global coverage rate.

PMID:
25732034
PMCID:
PMC4355249
DOI:
10.1101/cshperspect.a021493
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center